Sugi Predict

Sugi Predict / Compounds / SCHEMBL4375027

SCHEMBL4375027

SCHEMBL4375027

Cc1ccc(-c2nc(CCN3C(=O)c4ccccc4C3=O)cn2C(c2nc(C)c(C)c(=O)n2Cc2ccccc2)C(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ ALDH1A1 P00352 5/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CASR P41180 1/20 0.38
▸ PKM P14618 1/20 0.36
▸ CASP3 P42574 2/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ RGS4 P49798 1/20 0.35
▸ BRD4 O60885 1/20 0.34
▸ KIF11 P52732 1/20 0.34
▸ KIF23 Q02241 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ USP1 O94782 2/20 0.33
▸ WDR48 Q8TAF3 1/20 0.33
▸ ADRA1D P25100 1/20 0.33
▸ ADRA1A P35348 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4373915 0.88 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1MEN1KMT2ACASR
SCHEMBL4520233 0.85 KIF11 (0.47) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4523001 0.78 KIF11 (0.49) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL5110435 0.77 LMNA (0.38) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4507515 0.73 KIF11 (0.55) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4541819 0.73 CASR (0.41) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4541822 0.73 CASR (0.41) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4523593 0.72 KIF11 (0.57) SMN1; SMN2ALDH1A1MEN1KMT2AKIF11
SCHEMBL4516475 0.72 KIF11 (0.53) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL5806031 0.72 KIF11 (0.53) LMNASMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482343-B2 Compounds, methods and compositions CYTOKINETICS, INC. (US) 2009-01-27 — — US disclosed
US-20070135432-A1 Compounds, methods and compositions CYTOKINETICS, INC. 2007-06-14 — — US disclosed
US-7166595-B2 Compounds, methods and compositions CYTOKINETICS, INC. (US) 2007-01-23 — — US disclosed
EP-1503993-A4 COMPOUNDS, METHODS AND COMPOSITIONS CYTOKINETICS INC (US) 2006-05-03 — — EP disclosed
EP-1503993-A2 COMPOUNDS, METHODS AND COMPOSITIONS Cytokinetics, Inc. (US) 2005-02-09 — — EP disclosed
US-20040077662-A1 Compounds, methods and compositions CYTOKINETICS, INC. 2004-04-22 — — US disclosed
WO-2003094839-A2 PYRIMIDINONE COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2003-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077662-A1 Compounds, methods and compositions ALPP, PCNA, MKI67 LMNA 554/4885SMN1; SMN2 2350/4885ALDH1A1 2640/4885
US-20070135432-A1 Compounds, methods and compositions ALPP, PCNA, MKI67 LMNA 554/4885SMN1; SMN2 2350/4885ALDH1A1 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.